Ivy Rx Tirzepatide Review: Cost & Honest Verdict (2026)

Ivy Rx: $275/month for tirzepatide appears on the site, consistent with roster data describing tiered compounded GLP-1 pricing. Every fact here comes from the company's own published program.

What Ivy Rx is

Ivy Rx is a telehealth provider, offering tiered compounded semaglutide and tirzepatide programs. It serves all 50 states, with an online intake reviewed by a licensed clinician.

What Ivy Rx costs

$275/month at the starting dose. This is a "starting at" figure — dose-tier pricing beyond the starting point isn't independently confirmed on the pages checked this check.

Limited public disclosure

Worth flagging directly: limited public information exists about Ivy Rx's program details beyond pricing and molecule availability — no named compounding pharmacy, no accreditation badge, and no named clinical leadership were found.

The brand-vs-compounded question

Ivy Rx dispenses compounded tirzepatide, not the FDA-approved branded product. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Ivy Rx's real strength: both semaglutide and tirzepatide available through a tiered compounded program. The trade-offs: this review found very limited public information about the program beyond pricing, no named compounding pharmacy, and no visible accreditation. As with any GLP-1 program, and especially one this thin on public disclosure, ask directly about the compounding pharmacy and your state's coverage before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Ivy Rx's confirmed starting price is a reasonable baseline, but this review found very little else to verify — no named pharmacy and no accreditation badge. Ask directly before committing. For providers with fuller public disclosure, compare it against BiltRx or Fresh Day Meds. See our best tirzepatide providers ranking for the full field.